Ofatumumab Misses NHL Mark; Genmab Shares Take a Tumble
By Cormac Sheridan
Wednesday, August 19, 2009
Shares in Genmab A/S dropped sharply Tuesday on news that its anti-CD20 antibody ofatumumab failed to demonstrate a significant objective response rate in non-Hodgkins lymphoma (NHL) patients who were refractory to other treatments. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.